Pulmonary arterial hypertension associated with systemic sclerosis

References

• McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol.53(17), 1573–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis.62(11), 1088–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum.52(12), 3792–3800 (2005).
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis.66(7), 940–944 (2007).
   PubMed Web of Science ®Google Scholar
• Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest123(2), 344–350 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum.54(9), 3043–3050 (2006).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Presberg KW, Doyle RL et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest126(Suppl. 1), 78S–92S (2004).
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med.140(1), 37–50 (2004).
   PubMed Web of Science ®Google Scholar
• Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum. Dis. Clin. North Am.29(2), 211–237 (2003).
   PubMed Web of Science ®Google Scholar
• Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum.44(6), 1359–1362 (2001).
   PubMed Web of Science ®Google Scholar
• Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum.48(7), 1956–1963 (2003).
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Silver RM. Systemic sclerosis: environmental and occupational risk factors. Curr. Opin. Rheumatol.12(6), 520–526 (2000).
   PubMed Web of Science ®Google Scholar
• Mayes MD. Scleroderma epidemiology. Rheum. Dis. Clin. North Am.29(2), 239–254 (2003).
   PubMed Web of Science ®Google Scholar
• Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum.48(8), 2246–2255 (2003).
   PubMed Web of Science ®Google Scholar
• Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford)43(5), 596–602 (2004).
   PubMed Web of Science ®Google Scholar
• Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch. Dermatol. Res.283(6), 366–371 (1991).
   PubMed Web of Science ®Google Scholar
• Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum.40(3), 441–445 (1997).
   PubMed Web of Science ®Google Scholar
• Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford)43(9), 1129–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum.37(4), 223–235 (2008).
   PubMed Web of Science ®Google Scholar
• Laing TJ, Gillespie BW, Toth MB et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum.40(4), 734–742 (1997).
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis), classification, subsets and pathogenesis. J. Rheumatol.15(2), 202–205 (1988).
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol.28(7), 1573–1576 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson DA, Drane WE, Curran J et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch. Intern. Med.149(3), 589–593 (1989).
   PubMedGoogle Scholar
• Savarino E, Bazzica M, Zentilin P et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med.179(5), 408–413 (2009).
   PubMed Web of Science ®Google Scholar
• Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum.28(12), 1336–1340 (1985).
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum.52(8), 2415–2424 (2005).
   PubMed Web of Science ®Google Scholar
• Olsen NJ, King LE Jr, Park JH. Muscle abnormalities in scleroderma. Rheum. Dis. Clin. North Am.22(4), 783–796 (1996).
   PubMed Web of Science ®Google Scholar
• Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br. J. Rheumatol.37(12), 1320–1323 (1998).
   PubMedGoogle Scholar
• Vitali C, Viegi G, Tassoni S et al. Lung function abnormalities in different connective tissue diseases. Clin. Rheumatol.5(2), 181–188 (1986).
   PubMed Web of Science ®Google Scholar
• Lang B, Ortlieb H, Meske S, Hauke G, Peter HH. Progressive systemic sclerosis presenting with spontaneous pneumothorax. J. Rheumatol.16(2), 254–256 (1989).
   PubMed Web of Science ®Google Scholar
• Varga J. Systemic sclerosis: an update. Bull. NYU Hosp. Jt Dis.66(3), 198–202 (2008).
   PubMedGoogle Scholar
• Morelli S, Barbieri C, Sgreccia A et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J. Rheumatol.24(1), 81–85 (1997).
   PubMed Web of Science ®Google Scholar
• Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE. Lung involvement in systemic sclerosis (scleroderma), relation to classification based on extent of skin involvement or autoantibody status. Respir. Med.90(4), 223–230 (1996).
   PubMed Web of Science ®Google Scholar
• McNearney TA, Reveille JD, Fischbach M et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum.57(2), 318–326 (2007).
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum.43(11), 2437–2444 (2000).
   PubMed Web of Science ®Google Scholar
• Battle RW, Davitt MA, Cooper SM et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest110(6), 1515–1519 (1996).
   PubMed Web of Science ®Google Scholar
• Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum.29(4), 515–524 (1986).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med.173(9), 1023–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Avouac J, Airo P, Meune C et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J. Rheumatol.37(11), 2290–2298 (2010).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest137(2), 376–387 (2010).
   PubMed Web of Science ®Google Scholar
• Overbeek MJ, Vonk MC, Boonstra A et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur. Respir. J.34(2), 371–379 (2009).
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Humbert M, Perros F et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol.38(6), 893–902 (2007).
   PubMed Web of Science ®Google Scholar
• LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum. Dis. Clin. North Am.22(4), 675–694 (1996).
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity42(7), 587–595 (2009).
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum.43(11), 2550–2562 (2000).
   PubMed Web of Science ®Google Scholar
• Cerinic MM, Valentini G, Sorano GG et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin. Arthritis Rheum.32(5), 285–295 (2003).
   PubMed Web of Science ®Google Scholar
• Denton CP, Bickerstaff MC, Shiwen X et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br. J. Rheumatol.34(11), 1048–1054 (1995).
   PubMedGoogle Scholar
• Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res.4(6), R11 (2002).
   PubMedGoogle Scholar
• Choi JJ, Min DJ, Cho ML et al. Elevated vascular endothelial growth factor in systemic sclerosis. J. Rheumatol.30(7), 1529–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum.43(4), 889–893 (2000).
   PubMed Web of Science ®Google Scholar
• Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J. Rheumatol.36(3), 576–582 (2009).
   PubMed Web of Science ®Google Scholar
• Grigoryev DN, Mathai SC, Fisher MR et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl. Res.151(4), 197–207 (2008).
   PubMed Web of Science ®Google Scholar
• Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum.35(1), 95–100 (1992).
   PubMed Web of Science ®Google Scholar
• Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J. Intern. Med.265(6), 625–631 (2009).
   PubMed Web of Science ®Google Scholar
• Tamby MC, Chanseaud Y, Humbert M et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax60(9), 765–772 (2005).
   PubMed Web of Science ®Google Scholar
• Grigolo B, Mazzetti I, Meliconi R et al. Anti-topoisomerase II α autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin. Exp. Immunol.121(3), 539–543 (2000).
   PubMed Web of Science ®Google Scholar
• Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur. Respir. J.26(6), 1110–1118 (2005).
   PubMed Web of Science ®Google Scholar
• Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann. Rheum. Dis.69(2), 319–324 (2010).
   PubMed Web of Science ®Google Scholar
• Tamby MC, Humbert M, Guilpain P et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur. Respir. J.28(4), 799–807 (2006).
   PubMed Web of Science ®Google Scholar
• Tamby MC, Servettaz A, Tamas N et al. IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts. Biologics2(3), 583–591 (2008).
   PubMedGoogle Scholar
• Terrier B, Tamby MC, Camoin L et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.177(10), 1128–1134 (2008).
   PubMed Web of Science ®Google Scholar
• Riemekasten G, Philippe A, Nather M et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann. Rheum. Dis.70(3), 530–536 (2010).
   PubMed Web of Science ®Google Scholar
• Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest130(1), 182–189 (2006).
   PubMed Web of Science ®Google Scholar
• Jais X, Launay D, Yaici A et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum.58(2), 521–531 (2008).
   PubMed Web of Science ®Google Scholar
• Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin. Chest Med.28(1), 43–57, VII–VIII (2007).
   PubMed Web of Science ®Google Scholar
• Trembath RC, Thomson JR, Machado RD et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med.345(5), 325–334 (2001).
   PubMed Web of Science ®Google Scholar
• Girerd B, Montani D, Coulet F et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am. J. Respir. Crit. Care Med.181(8), 851–861 (2010).
   PubMed Web of Science ®Google Scholar
• Tew MB, Arnett FC, Reveille JD, Tan FK. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum.46(10), 2829–2830 (2002).
   PubMedGoogle Scholar
• Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J. Rheumatol.29(11), 2379–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Wipff J, Kahan A, Hachulla E et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford)46(4), 622–625 (2007).
   PubMed Web of Science ®Google Scholar
• Mattuzzi S, Barbi S, Carletto A et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J. Rheumatol.34(5), 997–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Dieude P, Guedj M, Wipff J et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann. Rheum. Dis.69(11), 1958–1964 (2010).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.165(6), 800–804 (2002).
   PubMed Web of Science ®Google Scholar
• Girgis RE, Frost AE, Hill NS et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann. Rheum. Dis.66(11), 1467–1472 (2007).
   PubMed Web of Science ®Google Scholar
• MacDonald SL, Rubens MB, Hansell DM et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology221(3), 600–605 (2001).
   PubMed Web of Science ®Google Scholar
• Mathai SC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum.60(2), 569–577 (2009).
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med.179(2), 151–157 (2009).
   PubMed Web of Science ®Google Scholar
• Campo A, Mathai SC, Le Pavec J et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.182(2), 252–260 (2010).
   PubMed Web of Science ®Google Scholar
• Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum.48(2), 516–522 (2003).
   PubMed Web of Science ®Google Scholar
• Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest124(6), 2098–2104 (2003).
   PubMed Web of Science ®Google Scholar
• Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild–moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J. Rheumatol.33(2), 269–274 (2006).
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Avouac J et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum.58(1), 284–291 (2008).
   PubMed Web of Science ®Google Scholar
• Steen VD. The many faces of scleroderma. Rheum. Dis. Clin. North Am.34(1), 1–15; V (2008).
   PubMed Web of Science ®Google Scholar
• Campo A, Mathai SC, Le Pavec J et al. Outcomes of hospitalization for right heart failure in pulmonary arterial hypertension. Eur. Respir. J. DOI: 10.1183/09031936.00148310 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Boueiz A, Mathai SC, Hummers LK, Hassoun PM. Cardiac complications of systemic sclerosis: recent progress in diagnosis. Curr. Opin. Rheumatol.22(6), 696–703 (2010).
   PubMed Web of Science ®Google Scholar
• Mathai SC, Bueso M, Hummers LK et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur. Respir. J.35(1), 95–104 (2010).
   PubMed Web of Science ®Google Scholar
• Forfia PR, Mathai SC, Fisher MR et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.177(12), 1364–1369 (2008).
   PubMed Web of Science ®Google Scholar
• Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron. Artery Dis.16(1), 13–18 (2005).
   PubMed Web of Science ®Google Scholar
• Overbeek MJ, Lankhaar JW, Westerhof N et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur. Respir. J.31(6), 1160–1166 (2008).
   PubMed Web of Science ®Google Scholar
• Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum.52(7), 2125–2132 (2005).
   PubMed Web of Science ®Google Scholar
• Mangat P, Conron M, Gabbay E, Proudman SM. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. Intern. Med. J.40(7), 494–502 (2010).
   PubMed Web of Science ®Google Scholar
• Huscher D, Pittrow D, Distler O et al. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin. Exp. Rheumatol.28(2 Suppl. 58), S47–S52 (2010).
   Google Scholar
• Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med.161(2 Pt 1), 487–492 (2000).
   PubMed Web of Science ®Google Scholar
• Avouac J, Kowal-Bielecka O, Pittrow D et al. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann. Rheum. Dis.69(7), 1360–1363 (2010).
   PubMed Web of Science ®Google Scholar
• Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest135(1), 137–142 (2009).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353(20), 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J. Rheumatol.36(2), 330–336 (2009).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol.40(4), 780–788 (2002).
   PubMed Web of Science ®Google Scholar
• Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J.27(5), 589–595 (2006).
   PubMed Web of Science ®Google Scholar
• Distler O, Behrens F, Pittrow D et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum.59(6), 867–875 (2008).
   PubMedGoogle Scholar
• Nagaya N, Uematsu M, Satoh T et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.160(2), 487–492 (1999).
   PubMed Web of Science ®Google Scholar
• Fijalkowska A, Kurzyna M, Torbicki A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest129(5), 1313–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Williams MH, Handler CE, Akram R et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J.27(12), 1485–1494 (2006).
   PubMed Web of Science ®Google Scholar
• Forfia PR, Fisher MR, Mathai SC et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med.174(9), 1034–1041 (2006).
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.333(4), 214–221 (1995).
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328(24), 1732–1739 (1993).
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.159(6), 1925–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J. Clin. Invest.115(6), 1461–1463 (2005).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111(23), 3105–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Pietra GG, Edwards WD, Kay JM et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation80(5), 1198–1206 (1989).
   PubMed Web of Science ®Google Scholar
• Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J.28(5), 999–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med.334(5), 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med.112(7), 485–491 (1990).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med.132(6), 425–434 (2000).
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Schilz RJ, Barst RJ et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest126(2), 420–427 (2004).
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am. Heart J.157(4), 625–635 (2009).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol.55(18), 1915–1922 (2010).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346(12), 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• Denton CP, Pope JE, Peter HH et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis.67(9), 1222–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant.24(10), 1626–1631 (2005).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.169(4), 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.46(3), 529–535 (2005).
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation119(22), 2894–2903 (2009).
   PubMed Web of Science ®Google Scholar
• Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann. Rheum. Dis.67(6), 808–814 (2008).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med.149(8), 521–530 (2008).
   PubMed Web of Science ®Google Scholar
• Mathai SC, Girgis RE, Fisher MR et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J.29(3), 469–475 (2007).
   PubMed Web of Science ®Google Scholar
• Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol.60(1), 107–112 (2005).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med.353(13), 1412–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med.145(2), 152–153 (2006).
   PubMed Web of Science ®Google Scholar
• Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax61(8), 736 (2006).
   PubMed Web of Science ®Google Scholar
• Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur. Respir. J.32(1), 232–235 (2008).
   PubMed Web of Science ®Google Scholar
• ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin. Res. Cardiol.98(4), 265–267 (2009).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med.182(9), 1171–1177 (2010).
   PubMed Web of Science ®Google Scholar
• Reich N, Maurer B, Akhmetshina A et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum.62(1), 280–290 (2010).
   PubMed Web of Science ®Google Scholar
• Maurer B, Busch N, Jungel A et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation120(23), 2367–2376 (2009).
   PubMed Web of Science ®Google Scholar
• Schachna L, Medsger TA Jr, Dauber JH et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum.54(12), 3954–3961 (2006).
   PubMed Web of Science ®Google Scholar
• Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev. Respir. Med.3(2), 187–196 (2009).
   PubMedGoogle Scholar
• Mathai SC, Hassoun PM. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr. Opin. Rheumatol.21, 642–648 (2009).
   PubMed Web of Science ®Google Scholar